Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
AstraZeneca
ImmunityBio, Inc.
Eli Lilly and Company
Vanderbilt-Ingram Cancer Center
Eli Lilly and Company
Glycotope GmbH
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company